Am J Psychiatry 155:751-760, June 1998
© 1998 American Psychiatric Association
Positive and Negative Symptom Response to Clozapine in Schizophrenic Patients With and Without the Deficit Syndrome
Robert W. Buchanan, M.D.,
Alan Breier, M.D.,
Brian Kirkpatrick, M.D.,
Patricia Ball, R.N., and
William T. Carpenter, Jr., M.D.
OBJECTIVE: In a preliminary report, the authors observed that clozapine was superior to haloperidol in the treatment of positive and negative symptoms in stable outpatients with schizophrenia. In this final report, they examine the effects of clozapine on positive and negative symptoms in patients with and without the deficit syndrome to determine which patients receive the positive symptom advantage of clozapine and the extent of clozapine's therapeutic effects on negative symptoms. In addition, they examine the long-term effects of clozapine on positive, negative, and affective symptoms, social and occupational functioning, and quality of life. METHOD: Seventy-five outpatients with schizophrenia, who met retrospective and prospective criteria for residual positive or negative symptoms, were entered into a 10-week double-blind, parallel-groups comparison of clozapine and haloperidol. Patients who completed the double-blind study were then entered into a 1-year open-label clozapine study. RESULTS: For patients who completed the 10-week double-blind study, clozapine was superior to haloperidol in treating positive symptoms. This effect was not observed in the intent-to-treat analyses. There was no evidence of any superior efficacy or long-term effect of clozapine on primary or secondary negative symptoms. Long-term clozapine treatment was associated with significant improvements in social and occupational functioning but not in overall quality of life. CONCLUSIONS: For schizophrenic patients who are able to tolerate clozapine therapy, clozapine has superior efficacy for positive symptoms but not negative symptoms and is associated with long-term improvements in social and occupational functioning for patients with and without the deficit syndrome
This article has been cited by other articles:
|
|
|
|
 
S. Galderisi, M. Quarantelli, U. Volpe, A. Mucci, G. B. Cassano, G. Invernizzi, A. Rossi, A. Vita, S. Pini, P. Cassano, et al.
Patterns of Structural MRI Abnormalities in Deficit and Nondeficit Schizophrenia
Schizophr Bull,
March 1, 2008;
34(2):
393 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov
Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features
Schizophr Bull,
February 26, 2008;
(2008)
sbn005v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Focus,
January 1, 2008;
6(2):
212 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Psychiatr Serv,
July 1, 2007;
58(7):
983 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Buchanan
Persistent Negative Symptoms in Schizophrenia: An Overview
Schizophr Bull,
July 1, 2007;
33(4):
1013 - 1022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Stone, P. D. Morrison, and L. S. Pilowsky
Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review
J Psychopharmacol,
June 1, 2007;
21(4):
440 - 452.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. F. Kim, A. S. Huang, A. M. Snowman, C. Teuscher, and S. H. Snyder
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase
PNAS,
February 27, 2007;
104(9):
3456 - 3459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I. Krakowski, P. Czobor, L. Citrome, N. Bark, and T. B. Cooper
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Arch Gen Psychiatry,
June 1, 2006;
63(6):
622 - 629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M Erhart, S. R Marder, and W. T Carpenter
Treatment of Schizophrenia Negative Symptoms: Future Prospects
Schizophr Bull,
April 1, 2006;
32(2):
234 - 237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Artaloytia, C. Arango, A. Lahti, J. Sanz, A. Pascual, P. Cubero, D. Prieto, and T. Palomo
Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers
Am J Psychiatry,
March 1, 2006;
163(3):
488 - 493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Buchanan, M. P. Ball, E. Weiner, B. Kirkpatrick, J. M. Gold, R. P. McMahon, and W. T. Carpenter Jr.
Olanzapine Treatment of Residual Positive and Negative Symptoms
Am J Psychiatry,
January 1, 2005;
162(1):
124 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chakos, J. Lieberman, E. Hoffman, D. Bradford, and B. Sheitman
Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Focus,
January 1, 2004;
2(1):
111 - 121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Freedman
Schizophrenia
N. Engl. J. Med.,
October 30, 2003;
349(18):
1738 - 1749.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Arango, A. Breier, R. McMahon, W. T. Carpenter Jr., and R. W. Buchanan
The Relationship of Clozapine and Haloperidol Treatment Response to Prefrontal, Hippocampal, and Caudate Brain Volumes
Am J Psychiatry,
August 1, 2003;
160(8):
1421 - 1427.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. MONCRIEFF
Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination
The British Journal of Psychiatry,
August 1, 2003;
183(2):
161 - 166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Davis, N. Chen, and I. D. Glick
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Arch Gen Psychiatry,
June 1, 2003;
60(6):
553 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. Dinakar, R. N. Sobel, J. H. Bopp, A. Daniels, and S. Mauro
Efficacy of Olanzapine and Risperidone for Treatment-Refractory Schizophrenia Among Long-Stay State Hospital Patients
Psychiatr Serv,
June 1, 2002;
53(6):
755 - 757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Galderisi, M. Maj, A. Mucci, G. B. Cassano, G. Invernizzi, A. Rossi, A. Vita, L. Dell'Osso, E. Daneluzzo, and S. Pini
Historical, Psychopathological, Neurological, and Neuropsychological Aspects of Deficit Schizophrenia: A Multicenter Study
Am J Psychiatry,
June 1, 2002;
159(6):
983 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Buchanan, J. Kreyenbuhl, J. M. Zito, and A. Lehman
Relationship of the Use of Adjunctive Pharmacological Agents to Symptoms and Level of Function in Schizophrenia
Am J Psychiatry,
June 1, 2002;
159(6):
1035 - 1043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Potkin, G. Alva, K. Fleming, R. Anand, D. Keator, D. Carreon, M. Doo, Y. Jin, J. C. Wu, and J. H. Fallon
A PET Study of the Pathophysiology of Negative Symptoms in Schizophrenia
Am J Psychiatry,
February 1, 2002;
159(2):
227 - 237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Dolder, J. P. Lacro, L. B. Dunn, and D. V. Jeste
Antipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents?
Am J Psychiatry,
January 1, 2002;
159(1):
103 - 108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Kane, S. R. Marder, N. R. Schooler, W. C. Wirshing, D. Umbricht, R. W. Baker, D. A. Wirshing, A. Safferman, R. Ganguli, M. McMeniman, et al.
Clozapine and Haloperidol in Moderately Refractory Schizophrenia: A 6-Month Randomized and Double-blind Comparison
Arch Gen Psychiatry,
October 1, 2001;
58(10):
965 - 972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chakos, J. Lieberman, E. Hoffman, D. Bradford, and B. Sheitman
Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Am J Psychiatry,
April 1, 2001;
158(4):
518 - 526.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Kapur and P. Seeman
Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Am J Psychiatry,
March 1, 2001;
158(3):
360 - 369.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. Kirkpatrick, R. W. Buchanan, D. E. Ross, and W. T. Carpenter Jr
A Separate Disease Within the Syndrome of Schizophrenia
Arch Gen Psychiatry,
February 1, 2001;
58(2):
165 - 171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mossman and D. S. Lehrer
Conventional and Atypical Antipsychotics and the Evolving Standard of Care
Psychiatr Serv,
December 1, 2000;
51(12):
1528 - 1535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Javitt, U. Heresco-Levy, N. B. Farber, J. W. Newcomer, and J. W. Olney
Are Glycine Sites Saturated In Vivo?
Arch Gen Psychiatry,
December 1, 2000;
57(12):
1181 - 1183.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kopelowicz, R. Zarate, K. Tripodis, V. Gonzalez, and J. Mintz
Differential Efficacy of Olanzapine for Deficit and Nondeficit Negative Symptoms in Schizophrenia
Am J Psychiatry,
June 1, 2000;
157(6):
987 - 993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Arango, B. Kirkpatrick, and R. W. Buchanan
Neurological Signs and the Heterogeneity of Schizophrenia
Am J Psychiatry,
April 1, 2000;
157(4):
560 - 565.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. D. Honey, E. T. Bullmore, W. Soni, M. Varatheesan, S. C. R. Williams, and T. Sharma
Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia
PNAS,
November 9, 1999;
96(23):
13432 - 13437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Wahlbeck, M. Cheine, A. Essali, and C. Adams
Evidence of Clozapine's Effectiveness in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Trials
Am J Psychiatry,
July 1, 1999;
156(7):
990 - 999.
[Abstract]
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1998
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
